

**Minutes of the meeting of the AREA PRESCRIBING COMMITTEE held on
Wednesday, 14th June 2023 via MS Teams**

MEMBERS:

Tom Bisset (Chair)	Community Pharmacist (LPC)
Dr Kapil Kapur	Consultant Gastroenterologist (BHNFT)

IN ATTENDANCE:

Nicola Brazier	Administration Officer (SYICB, Barnsley)
Deborah Cooke	Lead Pharmacist (SYICB, Barnsley)
Joanne Howlett	Medicines Management Pharmacist (SY ICB, Barnsley)
Matthew Tucker	Advanced Clinical Pharmacist (SWYPFT)
Gillian Turrell	Lead Pharmacist (BHNFT)
Tsz Hin Wong	Senior Interface Pharmacist (BHNFT)

APOLOGIES:

Professor Adewale Adebajo	Associate Medical Director (Medicines Optimisation) on behalf of the Medical Director (BHNFT)
Dr Mehrban Ghani	Chair, Barnsley Healthcare Federation CIC, representing the Primary Care Networks (PCNs)
Dr Madhavi Guntamukkala	Medical Director (SYICB, Barnsley)
Chris Lawson	Head of Medicines Optimisation (SYICB, Barnsley)
Dr Jeroen Maters	General Practitioner (LMC)
Dr Munsif Mufalil	General Practitioner (LMC)
Dr Abdul Munzar	General Practitioner (LMC)
Mike Smith	Chief Pharmacist (BHNFT)

**ACTION
BY**

APC 23/95 QUORACY

The Advanced Clinical Pharmacist was welcomed to the meeting, in attendance on behalf of SWYPFT until the new Lead Pharmacist starts in post.

The meeting was not quorate and therefore any proposed decisions/approvals will be ratified for endorsement either outside the meeting by email or at the next meeting.

APC 23/96 DECLARATIONS OF INTEREST RELEVANT TO THE AGENDA

There were no declarations of interest to note.

APC 23/97 DRAFT MINUTES OF THE MEETING HELD ON 10th MAY 2023

The minutes were accepted as an accurate record of the meeting.

Agreed action: -

- As the meeting was not quorate, approval will be obtained outside the meeting by email.

NB

Post meeting note: approval received by email; therefore, the minutes were accepted as an accurate record of the meeting.

APC 23/98
23/98.1

MATTERS ARISING AND APC ACTION PLAN

NICE TAs (March 2023)

The Lead Pharmacist, BHNFT **to advise** if the following NICE TAs are applicable for use at BHNFT: -

GT

- TA875 Semaglutide for managing overweight and obesity
- TA877 Finerenone for treating chronic kidney disease in type 2 diabetes

These are awaiting consultant feedback, and the clinical risk team are chasing a response.

23/98.2

NICE TAs (April 2023)

The Lead Pharmacist, BHNFT advised that the following NICE TA **was not** applicable for use at BHNFT: -

- TA880 Tezepelumab for treating severe asthma

The Lead Pharmacist, BHNFT **to advise** if the following NICE HSTs are applicable for use at BHNFT (awaiting feedback from the specialists): -

GT

- HST25 Lumasiran for treating primary hyperoxaluria type 1
- HST26 Eladocogene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency

23/98.3

South Yorkshire Integrated Medicines Optimisation Committee (SY IMOC) Traffic Light Drugs List (feedback from the LMC)

This item was deferred to the next meeting.

CL

23/98.4

Action Plan – other

Target dates

The Head of Medicines Optimisation and Lead Pharmacist, BHNFT have met and agreed the following amendments to target dates on the action plan: -

NB

- Combination anticoagulant and antiplatelet treatment for patients with concomitant AF and ACS Guideline – deferred to August 2023
- Dalteparin Shared Care Guidance – deferred to August 2023
- Empagliflozin for chronic heart failure with reduced ejection fraction Amber-G Guidance – deferred to August 2023
- Ticagrelor audit – outcome of audit to be shared including/following amendments made by BHNFT governance. It was noted that the audit data is quite out of date now, therefore once outcome of audit report is received, this action will be closed on the action plan. A new Ticagrelor audit action to be added, with a 6 month deadline.
- Hyperkalaemia Management Guideline (renal association guideline - community version) - moved to primary care lead and 6 month timeframe agreed.
- Icosapent Ethyl amber shared care guidance – 6 month extension agreed.
- Immunosuppressants - dermatology guidelines – need specialist input, 6 month extension agreed.
- Dexcom One Sheffield Position Statement/Barnsley guidance - CGM meeting still to take place. The IMOC have discussed

one guideline across South Yorkshire for adults and children and work on this has started.

APC 23/99 TREATMENT OF OVERACTIVE BLADDER IN WOMEN (MINOR UPDATE) AND MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS (LUTS) IN MEN (MINOR UPDATE)

The Medicines Management Pharmacist (SY ICB, Barnsley) presented the guidance documents which have received minor updates following recent formulary changes to preferred brands which were agreed by the Committee in a previous meeting. The following changes were noted.

For the Tolterodine MR 4mg od, Tolthen® XL is the preferred brand instead of Neditol® XL.

The solifenacin 1mg/ml oral solution has been changed to suspension as this is more cost effective.

Prices have been updated.

There were no issues raised by the LMC.

The Committee approved the updated Treatment of Overactive Bladder in Women and Management of Lower Urinary Tract Symptoms (LUTS) in Men guidance.

Agreed action: -

- As the meeting was not quorate, approval will be obtained outside the meeting by email.

JH

Post meeting note: approval received by email; therefore, the updated guidance was approved by the Committee.

APC 23/100 NHS ENGLAND COMMISSIONING RECOMMENDATIONS BLOOD GLUCOSE AND KETONE METERS, TEST STRIPS AND LANCETS (FOR INFORMATION)

The Lead Pharmacist (SY ICB, Barnsley) advised that the commissioning recommendations had been shared for information, following queries from primary care, noting that the recommendations are advisory rather than mandatory.

It is understood that the commissioning recommendations are to be discussed at the IMOC but there was currently no further update to note.

There are currently some differences between existing local guidance and the new national recommendations, and it was proposed, that unless the IMOC agreed otherwise, the Barnsley Place guidance would be reviewed against the commissioning recommendations in due course. It was noted that there has separately been a change to one of the first line blood glucose meters included in the Barnsley Place guidance which has recently been replaced with a meter which can test both glucose and ketones and is included in the commissioning recommendations. As an interim measure it was agreed that the guideline would be updated with these minor changes to support practices with the Medicines Optimisation Scheme work.

APC 23/101 SUPPLY OF COVID MEDICINES

An update provided to the Chair by the Head of Medicines Optimisation was shared, with reference to the paper (enclosure M) discussed at the June 2023 IMOC meeting, summarising proposed changes to the commissioning arrangements for supply of COVID medicines. The paper summarised planning for the first line oral (antiviral) Paxlovid® being prescribed within primary care from the end of June 2023. After discussion and noting significant concerns from LMC representatives, all medications, including oral Paxlovid® maintained red traffic light classification status due to GPs being unfamiliar with the medications. It was understood that the current CMDU pathway/arrangements for supply would remain in place until the new pathway was agreed and introduced. The position will be reviewed by the IMOC in light of pathway developments.

Following discussion, the Community Pharmacist and Lead Pharmacist, BHNFT wanted to seek further clarity around the continuation of the current arrangements for secondary care to prescribe and supply medicines. Clarity would be required as soon as possible to manage stock at BHNFT.

The Community Pharmacist advised that any plan regarding change in provision has not yet been agreed with the LPCs.

Agreed actions: -

- Clarity to be sought from the Head of Medicines Optimisation around provision from the end of June 2023.
- The Lead Pharmacist, BHNFT to check if colleagues in CMDU are aware of any arrangement in place to provide COVID medicines beyond the end of June 2023.

TB/CL

GT

Post meeting note: - Information from SYICB Chief Pharmacy Officer sent to GP practices and community pharmacies 26th June 2023 outlining new arrangements. The letter sent to GP practices notes that Covid treatments are currently red drugs in South Yorkshire and GP practices should not prescribe, patients should be referred to the local acute Trust for triage and treatment via the standard urgent referral route. This position will be reviewed in due course. A small number of community pharmacies have expressed an interest to stock and dispense Paxlovid®.

APC 23/102 SHARED CARE GUIDELINES/AMBER G SHARED CARE GUIDELINES

No guidelines to approve this month.

APC 23/103 FORMULARY REVIEWS

23/103.1

Formulary Review Plan

There were no changes to note.

APC 23/104 NEW PRODUCT APPLICATION LOG

The new product application log was received for information with no changes to note.

APC 23/105 REGIONAL MEDICINES OPTIMISATION COMMITTEE (RMOC) & SOUTH YORKSHIRE INTEGRATED MEDICINES OPTIMISATION COMMITTEE (SY IMOC)

23/105.1 SYICB IMOC Ratified Minutes, 5th April 2023 & 3rd May 2023

The minutes were shared for information, noting the summary of points and recommendations approved documented at the end of each set of minutes.

23/105.2 SYICB IMOC – Verbal key points - 7th June 2023

At the June 2023, it was identified that an assurance process of communication and engagement with stakeholders in each area was required to be undertaken to ensure recommendations approved by the IMOC are fed back appropriately at Place. Barnsley LMC have confirmed that they feel engagement through the Head of Medicines Optimisation and their SY LMC representative (which is Place) is currently sufficient and working well.

It was recognised that some pathways were not as firm as they could be, with some of the business not moving as quickly as planned, but the IMOC was work in progress. The Community Pharmacist thanked Barnsley Place colleagues for the work undertaken on the Horizon Scanning document and the work done in building for the IMOC.

23/105.3 ICB TLDL – principles for development

The Lead Pharmacist (SY ICB, Barnsley) presented enclosure H for information, noting that a subgroup has been established with representation from all SY Places, with the Lead Pharmacist and Medicines Management Pharmacist, (SY ICB, Barnsley) representing Barnsley Place. The group are currently working through the different traffic light lists, starting with the grey list trying to agree a standard IMOC traffic light list. This is work in progress. Enclosure H summarises some of the principles the group are following.

APC 23/106 BARNSELY APC REPORTING

23/106.1 APC Reporting April 2023

The Lead Pharmacist, (SY ICB, Barnsley) presented the enclosure showing reports received directly into the APC reporting mailbox. There were 30 APC reports received for the month of April 2023.

23/106.2 APC Reporting April 2023 Key Themes

The summary report was presented, showing 55 reports in total, including 30 received directly into the APC reporting mailbox and 25 interface queries received directly to the BHNFT pharmacy team for the month of April 2023.

From the category breakdown, the largest key theme this month is D1 communication, plus other themes including shared care, formulary related, other hospital communication, and prescribing errors.

Details relating to some of the significant issues from APC reports (D1 communication/other discharge related, other hospital communication, formulary or guideline related, dispensing, and other) were shared and highlighted.

It was highlighted that a number of queries and reports have been received, and will come to a future meeting, in relation to requests for

primary care to prescribe and manage Entresto® from the outset when the shared care guideline states that the specialist will prescribe for the first 12 weeks. It was noted that Entresto® was on the APC action plan for some time with a view to looking at the pathway but it was agreed in the last meeting to remove this action. The Lead Pharmacist, BHNFT confirmed that this has been picked up within the Trust, who are establishing an MDT heart failure clinic (one per month) to initiate treatment which should negate these issues. With regards to BAPC23/04/11, it was understood that the Rotherham policy was being updated and the Lead Pharmacist (SY ICB, Barnsley) advised she would obtain further information to be shared with the Community Pharmacist, who offered to pick this up and progress on behalf of South Yorkshire if required.

With regards to BAPC23/04/04, a general lack of awareness of the on demand specialist drugs service (which is sometimes also referred to as the palliative care stockist scheme) was identified, therefore an article has been drafted for the next MMT newsletter to raise further awareness of the scheme which has been in place for many years. This would be shared with the Community Pharmacist to include in the LPC newsletter as well. The Lead Pharmacist (SY ICB, Barnsley) would also look at linking it to search terms on the BEST website to make it more accessible.

An update provided to the Chair by the Head of Medicines Optimisation was shared, noting that all SY ICB Barnsley Clinical Pharmacists now have access to BHNFT IT systems and are reporting benefits of resolving issues without approaching BHNFT. The number of APC reports received going forward will be monitored to see if a lower volume is captured by BHNFT. SWYPFT access is still being progressed and the Lead Pharmacist, BHNFT agreed to contact Richard Billam, Deputy Director of ICT to help provide the required access.

Agreed actions: -

- The Lead Pharmacist (SY ICB, Barnsley) to share a copy of the draft MMT newsletter article on the scheme with the Community Pharmacist for inclusion in the LPC newsletter also. DC
TB
- The Lead Pharmacist (SY ICB, Barnsley) to look at linking the scheme search terms on the BEST website to make it more accessible. DC
- The Lead Pharmacist, BHNFT agreed to contact Richard Billam to help provide the required access for SWYPFT. GT

23/106.3 APC Reporting April 2023 Interface Issues
The enclosure detailing the interface queries received directly within BHNFT pharmacy team was received and noted.

23/106.4 Primary Care Feedback - Post Natal Scripts of Dalteparin Shared Care
The Lead Pharmacist (SY ICB, Barnsley) raised on behalf of primary care a general issue with BHNFT issuing 4 week supply instead of the required 6 week supply, questioning why a shared care is being sent to the GP when BHNFT can issue the 6 week supply. The shared

care guidance advises that the full supply should be supplied by the hospital.

The Lead Pharmacist, BHNFT advised that the pharmacy team would routinely issue a 6 week supply, therefore asked that specific examples be provided for investigation.

Agreed actions: -

- The Lead Pharmacist (SY ICB, Barnsley) to feed this update back and obtain further information/examples for investigation.
- On receipt of further information/specific examples, the Lead Pharmacist, BHNFT to investigate, and advise service clinicians if required that the full 6 week supply should be supplied by the hospital.

DC

GT

23/106.5

Primary Care Feedback - Issues with DNs requesting dressings from GPs

The Lead Pharmacist (SY ICB, Barnsley) raised on behalf of primary care (primary issue only), issues with district nurses requesting dressings from GPs instead of accessing via ONPOS and it was noted that the Head of Medicines Optimisation was investigating the issues reported. It was noted that 85% of dressings supplied by Barnsley primary care are through the ONPOS system.

The Community Pharmacist advised that he plans to attend a future meeting of the Wound Care Advisory Group to discuss dressings requested by district nurses.

It was noted that only podiatry dressings remain to be issued via prescription by SWYPFT and BHNFT (small volume), but it was planned that podiatry would start using ONPOS and the dressings list would be reviewed to include all the dressings on the podiatry formulary. In interim, GP practices were asked to challenge any request for dressings recommended by community nurses. Information would be included in the MMT newsletter.

Agreed action: -

- Information to be included in the MMT newsletter.

DC/CL

Post meeting update:

Podiatry are currently using FP10 prescriptions for dressings. MMT members are working with SWYFT colleagues in regard to the introduction of ONPOS for the Podiatry teams. Due to increase workloads within the podiatry service, discussions are still in the early stages.

APC 23/107
23/107.1

NEW NICE TECHNOLOGY APPRAISALS (MAY 2023)
NICE TAs May 2023

The Lead Pharmacist, BHNFT advised that the following NICE TAs **were** applicable for use at BHNFT (formulary red classifications): -

- TA888 Risankizumab for previously treated moderately to severely active Crohn's disease
- TA891 Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia

The Lead Pharmacist, BHNFT advised that the following NICE TAs **were not** applicable for use at BHNFT: -

- TA881 Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments
- TA883 Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (not recommended)
- TA884 Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)
- TA885 Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
- TA886 Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
- TA887 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
- TA889 Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)
- TA890 Difelikefalin for treating pruritus in people having haemodialysis
- TA892 Mosunetuzumab for treating relapsed or refractory follicular lymphoma (not recommended)

The Lead Pharmacist, BHNFT **to advise** if the following NICE TA is applicable for use at BHNFT: -

- TA882 Voclosporin with mycophenolate mofetil for treating lupus nephritis

GT

23/107.2 Feedback from BHNFT Clinical Guidelines and Policy Group
There was nothing relevant to report.

23/107.3 Feedback from SWYPFT NICE Group
The Group are in process of reviewing the antidepressant policy in line with new NICE guidance.

APC 23/108 **FEEDBACK FROM THE MEDICINES MANAGEMENT GROUPS**
23/108.1 Primary Care Quality & Cost-Effective Prescribing Group (QCEPG)
There was nothing relevant to report.

23/108.2 BHNFT
The Lead Pharmacist advised that the Group discussed some of the oxygen incidents that have been received into the Trust. These have been escalated to the new BHNFT Oxygen Steering Group, noting that one of the Senior Respiratory Consultants has reviewed all the patients and produced a report. The Lead Pharmacist planned to follow up with Laura Gill, Senior Respiratory Nurse, BREATHE Service regarding next steps and feedback to the APC.

Agreed action: -

- The Lead Pharmacist, BHNFT to follow up with Laura Gill.

GT

23/108.3 SWYPFT Drug and Therapeutics Committee
There was nothing relevant to report.

23/108.4 Community Pharmacy Feedback
23/108.4.1 LPC
The Community Pharmacist advised that from the end of June 2023, the Barnsley LPC will merge into a South Yorkshire LPC, known as Community Pharmacy South Yorkshire. There will be a representative attending the Barnsley APC meetings, likely to continue to be the Community Pharmacist in the short term.

23/108.4.2 National Contract
Feedback was provided regarding the national contract, noting the advice to pharmacies from Community Pharmacy England (was PSNC), in relation to provision of additional/advanced services and capacity to deliver those services. This could have an impact on delivering services such as the newly commissioned contraception service.

23/108.4.3 Opening Hours
From 25th May 2023, pharmacies can apply to change their opening hours. 100 hour pharmacies can apply to reduce their opening hours to 72 hours, keeping within core hours.

23/108.4.4 Consolidation/Change of Ownership/Closures
Update provided on pharmacy consolidation applications, noting one change and another in progress in Barnsley, delivering the same service but less physical buildings on the high street or in GP surgeries.

It was noted that there would be no Lloyds pharmacies in Barnsley from the end of July 2023 (change of ownership).

More pharmacy closures and reduction in opening hours were expected over the next 12 months.

In response to a query about potential impact on palliative care and communicating information more widely on consolidation and change to opening hours, the Community Pharmacist advised that accurate information on community pharmacy opening hours was available at www.nhs.uk. No impact/issue on palliative care provision was expected but it was suggested that the palliative care staff/team and district nurses should be informed that pharmacies are changing, and accurate information can be found at www.nhs.uk.

MT

23/108.5 Wound Care Advisory Group
There has been no meeting, therefore there was nothing to report.

APC 23/109 ISSUES FOR ESCALATION TO THE BARNSELY PLACE QUALITY & SAFETY COMMITTEE
There were no issues to escalate.

APC 23/110 FORMULARY ACTIONS
23/110.1 SPS New Medicines Newsletter April 2023
Received for information.

23/110.2 IMOC Horizon Scanning June 2023
The Medicines Management Pharmacist (SY ICB, Barnsley) presented the IMOC Horizon Scanning document, noting that the

purpose of this document is to support the IMOC in assigning a traffic light classification. Formulary status should continue to be agreed at place in line with local processes. The Committee assigned the following formulary classifications to the products listed below: -

- Ripretinib (Qinlock®) 50mg tablet (new medicine) – non-formulary grey
- Tecvistamab (Tecvayli®) 30mg in 3mL and 153mg in 1.7mL vials (new medicine) – non-formulary grey
- Tozinameran + famtozinameran (Comirnaty® Original/Omicron BA.4/5) (new medicine) – formulary green
- Cholera vaccine (Vaxchora®) (new medicine) – formulary green
- Eroxon Stimgel (single dose gel) (new medical device) – non-formulary grey
- Hepatitis A vaccine (Avaxim Junior®) (new medicine) – formulary green
- Ranibizumab biosimilar (Byooviz®) (new medicine) – non-formulary red
- Ranibizumab biosimilar (Ximluci®) (new medicine) – non-formulary red
- Tezepelumab (Tezspire®) (new medicine) – non-formulary red
- Fludroxycortide 0.0125% cream – formulary grey

Agreed action: -

- As the meeting was not quorate, approval will be obtained outside the meeting by email.

JH

Post meeting note: approval received by email; therefore, the formulary changes were approved by the Committee.

23/110.3

IMOC Horizon Scanning COVID Drugs

The Medicines Management Pharmacist (SY ICB, Barnsley) presented the IMOC Horizon Scanning COVID Drugs document, noting that the purpose of this document is support the IMOC in assigning a traffic light classification. Formulary status should continue to be agreed at place. The Committee assigned the following formulary classifications to the products listed below: -

- Remdesivir – formulary red
- Molnupiravir – formulary red
- Nirmatrelvir plus Ritonavir (Paxlovid) – formulary red
- Sotrovimab – formulary red
- Tocilizumab – formulary red
- Casirivimab plus imdevimab – brand name Ronapreve® – non-formulary grey (NICE TA not recommended)
- Baricitinib – formulary red

As discussed above at 23/101, clarification was to be obtained around the commissioning arrangements for provision of Paxlovid® from the end of June 2023.

Agreed actions: -

- Clarification to be obtained around the commissioning arrangements for provision of Paxlovid® from end of June 2023.
- Clarity required on pathway to confirm formulary status.
- As the meeting was not quorate, approval will be obtained outside the meeting by email.

CL

CL
JH

Post meeting note: - Information from SYICB Chief Pharmacy Officer sent to GP practices and community pharmacies 26th June 2023 outlining new arrangements. The letter sent to GP practices notes that Covid treatments are currently red drugs in South Yorkshire and GP practices should not prescribe, patients should be referred to the local acute Trust for triage and treatment via the standard urgent referral route. This position will be reviewed in due course. A small number of community pharmacies have expressed an interest to stock and dispense Paxlovid®.

Post meeting note: approval received by email; therefore, the formulary changes were approved by the Committee.

23/110.4

IMOC Traffic Light List Classifications – changes for Barnsley Place
The Medicines Management Pharmacist (SY ICB, Barnsley) presented enclosure N with amendments to the Barnsley grey list classifications which have so far been reviewed. This will be taken back to the July IMOC meeting, after being seen by each Place APC to receive any comments.

The following changes affecting Barnsley Place were highlighted: -

- Agomelatine – changed from non-formulary red to non-formulary grey (NICE TA)
- Amifampridine (3,4 diaminopyridine phosphate) – changed from non-formulary red to non-formulary grey
- Anakinra – currently formulary red with a link to NICE TA685 – suggesting red in line with the NICE TA, with a separate formulary grey entry for use in rheumatoid arthritis
- Armour thyroid – changed from formulary grey to non-formulary grey
- Belzutifan – changed from non-formulary provisional red to non-formulary grey (NICE TA in development)
- Bemiparin – changed from non-formulary provisional amber to non-formulary grey
- Erenumab – changed from non-formulary provisional grey to non-formulary red

The Community Pharmacist referred to atorvastatin 30mg and 60mg tablets (which are currently in short supply), noting that the published Drug Tariff prices are not the concession prices, with a request to have an awareness of this. This caveat would be fed back to the IMOC.

JH

It was noted that the brand names listed against anakinra were incorrect, which has been fed back and will be amended prior to the list going back to the IMOC.

The Medicines Management Pharmacist (SY ICB, Barnsley) highlighted further formulary changes from the April and May 2023 IMOC meetings.

IMOC - April 2023

The gluten free products were assigned an amber G classification by IMOC. Bread and mixes which are currently formulary green in Barnsley will change to formulary amber G. All other products will be kept as a separate entry as non-formulary grey.

IMOC - May 2023

Glucagon pre-filled pen (Ogluo®) was assigned an amber G classification by IMOC. This is currently non-formulary provisional grey in Barnsley but proposed to change to non-formulary amber G, with discussions to be held at Place regarding how this is implemented.

Cyanocobalamin tablets (CyanocoMinn®) was assigned a dual traffic light classification, assigned grey for use as a dietary supplement in line with NHS England Self Care Guidance and assigned green, as per the exceptions in the NHS England Self Care Guidance (only to be prescribed in those with medical diagnosed deficiency but should be reviewed on a regular basis). Further information will be added to the formulary to reflect this change in Barnsley.

The traffic light classification changes were accepted by the Committee.

Agreed action: -

- As the meeting was not quorate, approval will be obtained outside the meeting by email.

JH

Post meeting note: Approval requested by email. Feedback received regarding CyanocoMinn dual classification, additional wording will be added to the formulary to clarify that the green classification remains for patients who require treatment for clinical reasons such as non-diet related deficiency and the grey classification relates to use as a nutritional supplement in line with the NHS England guidance. Approval otherwise received; the traffic light classification changes were approved by the Committee.

APC 23/111 MHRA DRUG SAFETY UPDATE (MAY 2023)

The update was noted with the following information highlighted: - Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment
Risk minimisation materials are available to support the safe use of new paediatric formulations of rivaroxaban (Xarelto®) and dabigatran etexilate (Pradaxa®). In addition, we ask healthcare professionals to consult the current advice to ensure that all patients with renal impairment receive an appropriate dose of DOAC medicines.

Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease

Caution is required if prescribing febuxostat in patients with pre-existing major cardiovascular disease, particularly, in those with evidence of high urate crystal and tophi burden or those initiating urate-lowering therapy. This article replaces advice issued in Drug Safety Update published in July 2019.

The link to the new MHRA advice will be updated when the Barnsley guidance on Febuxostat is reviewed.

APC 23/112 SOUTH YORKSHIRE AREA PRESCRIBING COMMITTEE MINUTES (FOR INFORMATION)

The minutes from NHS South Yorkshire ICB Sheffield (20th April 2023) and NHS South Yorkshire ICB Doncaster & Bassetlaw (27th April 2023) were received and noted.

APC 23/113 ANY OTHER BUSINESS

23/113.1 Trainee Pharmacist Programme

The Lead Pharmacist, BHNFT advised that the Trainee Pharmacist Programme was changing, noting that from January 2024, the Trust needed to be able to offer a 13 week cross sector placement within primary care (funded by HEE).

To progress this, it was agreed that details would be emailed to the Head of Medicines Optimisation and Community Pharmacist.

Agreed action: -

- Details to be emailed to the Head of Medicines Optimisation and Community Pharmacist to assist with formalising the 13 week cross sector placement.

**GT
CL/TB**

APC 23/114 DATE AND TIME OF THE NEXT MEETING

The time and date of the next meeting was confirmed as Wednesday, 15th July 2023 at 12.30 pm via MS Teams.